Company news

Apotex Health Corp. news in 2026

Apotex Health Corp.'s news releases, calls and decks from 2026, newest first.

View company

Apotex launches APO-LINAGLIPTIN™, expanding access to treatment options for Canadians living with type 2 diabetes

November 17, 2026

Apotex launches Axitinib Tablets in the U.S., the first generic version of INLYTA®

November 16, 2026

Apotex to Participate in the Jefferies Global Healthcare Conference in London

November 16, 2026

Apotex Delivers Strong Second Quarter 2027 Results and Raises FY2027 Guidance

November 12, 2026

Apotex to Announce Second Quarter Fiscal 2027 Financial Results and Host Conference Call on November 12, 2026

October 8, 2026

Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering

October 5, 2026

Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering

September 28, 2026

Apotex Announces First Quarter 2027 Results

August 12, 2026

Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement

July 16, 2026

Apotex to Announce First Quarter Fiscal 2027 Financial Results and Host Conference Call on August 12, 2026

July 9, 2026

Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection

July 8, 2026

Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals

July 1, 2026

Apotex first to receive Health Canada approval for SEVMIA(TM), a generic semaglutide for chronic weight management

June 30, 2026

Apotex Health Corp. announces closing of upsized initial public offering and exercise of Over-Allotment option in full

June 16, 2026

Apotex Health Corp. (APTX) Opens the Market

June 11, 2026

Apotex Health Corp. files final prospectus and announces pricing of upsized initial public offering

June 9, 2026

Calls in 2026

Decks in 2026